Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma

NCT07487402 | Not Yet Recruiting Early Phase 1

• 1 other identifier: LM-META10-GPC3-13
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.

Conditions

Hepatocellular Carcinoma (HCC)

Keywords

Meta10-GPC3; unresectable recurrent/metastatic hepatocellular carcinoma; IL-10

Outcome Measures

Primary Outcomes (1)

• Adverse Events (AEs)

  To characterize the safety profile of Meta10-GPC3 in patients with unresectable recurrent/metastatic hepatocellular carcinoma as assessed by incidence of adverse events. Adverse events will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

  Within 2 years post Meta10-GPC3 infusion.

Secondary Outcomes (7)

• Objective response rate (ORR)

  12 week, 20 week, 28 week, 40 week, 52 week, 78 week, 104 week post Meta10-GPC3 infusion.

• Duration of Response (DOR)

  12 week, 20 week, 28 week, 40 week, 52 week, 78 week, 104 week post Meta10-GPC3 infusion.

• Progression-free survival (PFS)

  12 week, 20 week, 28 week, 40 week, 52 week, 78 week, 104 week post Meta10-GPC3 infusion.

• Overall survival (OS)

  12 week, 20 week, 28 week, 40 week, 52 week, 78 week, 104 week post Meta10-GPC3 infusion

• The maximum concentration (Cmax)

  Within 2 years post Meta10-GPC3 infusion.

Study Arms (1)

Administration of Metabolically Armed GPC3 CAR-T Therapy

EXPERIMENTAL

Patients undergo peripheral blood collection. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. The study will design metabolically armed GPC3 CAR-T cells(Meta10-GPC3) with different structures. A dose of Meta10-GPC3 CAR-T cells will be infused on day 0.

Drug: Metabolically Armed GPC3 CAR-T cells

Interventions

Metabolically Armed GPC3 CAR-T cells DRUG

Each subject receive metabolically armed GPC3 CAR- T cells by intravenous infusion.

Also known as: Meta10-GPC3

Administration of Metabolically Armed GPC3 CAR-T Therapy

Eligibility Criteria

• Age: 19 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>18 years and ≤75 years, male or female.
• Histologically confirmed recurrent or metastatic hepatocellular carcinoma (HCC) that is not amenable to surgical resection.
• At least one measurable target lesion according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
• Tumor tissue must test positive for GPC3 expression by immunohistochemical (IHC), defined as \> 25% of tumor cells staining for GPC3 in the pathological specimen. Preferably, the target lesion sample should be used, including freshly obtained tumor tissue or archival tissue samples deemed acceptable by the investigator.
• Expected survival ≥ 12 weeks.
• Child-Pugh class A.
• Eastern Cooperative Oncology Group (ECOG) performance status was 0-1.
• For subjects who are HBsAg or HBcAb positive, HBV-DNA must be \< 2 000 IU/mL; HBsAg-positive patients must receive antiviral therapy according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition).
• Adequate venous access for leukapheresis or venous blood collection.
• Hematologic parameters: WBC ≥ 2.5 × 10⁹/L, platelets ≥ 60 × 10⁹/L, Hb ≥ 9.0 g/dL, lymphocytes ≥ 0.4 × 10⁹/L.
• Biochemical parameters: Serum albumin ≥ 30 g/L; Lipase and amylase ≤ 1.5 × ULN; serum creatinine ≤ 1.5 × ULN and estimated creatinine clearance ≥ 40 mL/min; ALT and AST ≤ 5 × ULN; serum total bilirubin ≤ 2.5 × ULN; prothrombin time ≤ 4s longer above normal.
• Women or childbearing potential must have a negative serum pregnancy test within 14 days before CAR-T cell infusion and agree to use effective contraception for 12 months after infusion. Male subjects with partners of childbearing potential must having undergone a vasectomy or agree to use reliable contraception during the study period.
• Ability to understand and sign the informed consent form.

You may not qualify if:

• Pregnant or breastfeeding women, or women of childbearing potential who test positive on a pregnancy test during the screening period).
• Active hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection; seropositivity for Human Immunodeficiency (HIV) or syphilis.
• Any uncontrolled active infection, including but not limited to active pulmonary tuberculosis.
• Therapeutic doses of corticosteroids must be discontinued at least 2 weeks prior to Meta10-GPC3 infusion; any immunosuppressive medications must be discontinued at least 4 weeks before signing the informed consent form.
• History of hypersensitivity to immunotherapy or related agents, β-lactam antibiotics, or other severe allergic reactions.
• History or presence of hepatic encephalopathy.
• Clinically significant ascites, defined as ascites detectable on physical examination or requiring therapeutic intervention (excluding ascites detected only by imaging that does not require intervention).
• Imaging showing that HCC occupies ≥ 50 % of normal liver volume, or presence of tumor thrombus in the main portal vein or inferior vena cava.
• Clinically significant central-nervous-system (CNS) disorders (excluding subjects with CNS HCC metastases).
• Active or decompensated cardiac illness (requiring hospitalization or surgical intervention within the past 6 months), or poorly pression ≥ 160/100 mmHg uncontrolled with medication. Stable coronary artery disease or well-controlled hypertension is allowed.
• Active autoimmune disease requiring immunosuppressive therapy.
• Prior organ transplantation or currently on an organ transplant waiting list (including but not limited to liver transplantation).
• Any anti-HCC therapy within 2 weeks prior to leukapheresis or blood collection, including but not limited to surgical resection, interventional therapy, radiotherapy, chemotherapy, or immunotherapy.
• History or concurrent presence of other malignancies, except for the following: surgically removed non-melanoma skin cancer, cured cervical carcinoma in situ, localized prostate cancer, low-stage bladder cancer, ductal carcinoma in situ of the breast, or any malignancy without recurrence or treatment within the past 2 years.
• Other severe medical conditions, including but not limit to: poorly controlled diabetes (post-treatment HbA1c \> 7 %), severe cardiac dysfunction (LVEF \< 45 %), myocardial infarction, unstable angina, or unstable arrhythmia within 6 months, pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease, forced expiratory volume in 1 second (FEV1) \< 60 %, gastric ulcer, history of gastrointestinal bleeding, documented bleeding diathesis, uncontrolled thrombotic events, major bleeding, or DVT within 12 months prior to informed consent.

Sponsors & Collaborators

• Zhejiang University: lead
• Leman Biotech Co., Ltd.: collaborator

Study Sites (1)

The first affiliated hospital of medical college of zhejiang university

Hangzhou, Zhejiang, 310000, China

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Central Study Contacts

Qihan Fu

CONTACT

18268173309; ayfuqihan@126.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 17, 2026
• First Posted: March 23, 2026
• Study Start: March 30, 2026
• Primary Completion (Estimated): December 15, 2028
• Study Completion (Estimated): April 15, 2029
• Last Updated: April 21, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)